UNION therapeutics announces full-year results for 2023
Hellerup, Denmark, February 7, 2024, – UNION therapeutics A/S (“UNION”), a privately held, clinical stage, pharmaceutical development company focused on immunology, announces full-year results for the period January 1 to December 31, 2023. 2023 has been a year of great progress for UNION with positive read-outs from two clinical studies with lead candidate orismilast, a next-generation, high potency PDE4B/D inhibitor, in psoriasis and hidradenitis suppurativa (HS). Results have been presented at leading scientific conferences and published in peer-reviewed journals. Additionally, patient